ALLR RSI Chart
Last 7 days
-19.0%
Last 30 days
-57.3%
Last 90 days
-92.1%
Trailing 12 Months
-99.7%
Which funds bought or sold ALLR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -20,694 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 3.32 | -1,329 | 1,722 | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 2.00 | 2.00 | -% |
May 13, 2024 | UBS Group AG | new | - | 9,941 | 9,941 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 12.5 | -7.00 | 11.00 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Feb 26, 2024 | Virtu Financial LLC | reduced | -41.83 | -11,000 | 8,000 | -% |
Unveiling Allarity Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Allarity Therapeutics, Inc. News
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | 0.9% | 11,969 | 11,862 | 13,875 | 13,426 | 12,702 | 14,544 | 18,134 | 23,231 | 31,290 | 49,633 | 36,987 | 38,780 | 36,092 | 33,403 | 31,607 |
Current Assets | 16.4% | 2,295 | 1,971 | 4,387 | 3,686 | 2,966 | 4,968 | 6,061 | 10,119 | 17,211 | 21,404 | 7,635 | 8,497 | - | 1,715 | 3,343 |
Cash Equivalents | 88.0% | 312 | 166 | 1,399 | 351 | 295 | 2,029 | 3,946 | 7,677 | 14,544 | 19,555 | 5,584 | 6,598 | 105 | 298 | 1,524 |
Net PPE | -10.0% | 18.00 | 20.00 | 29.00 | 26.00 | 25.00 | 21.00 | 5.00 | 5.00 | 6.00 | 8.00 | 9.00 | 10.00 | - | 21.00 | 37.00 |
Liabilities | 26.2% | 18,440 | 14,613 | 17,254 | 14,149 | 13,041 | 12,654 | 14,631 | 13,149 | 14,416 | 30,849 | 7,326 | 9,960 | 9,462 | 8,964 | 10,704 |
Current Liabilities | 27.1% | 18,008 | 14,167 | 15,744 | 12,668 | 11,588 | 11,222 | 12,955 | 11,462 | 12,711 | 20,719 | 3,838 | 4,335 | - | 5,533 | 4,719 |
Long Term Debt | - | - | - | - | - | - | - | - | 812 | - | 785 | 773 | - | - | 737 | - |
LT Debt, Current | - | - | - | - | - | 2,687 | 2,644 | - | - | - | - | - | - | - | 1,327 | - |
Shareholder's Equity | -135.2% | -6,471 | -2,751 | - | - | -3,102 | -113 | 1,447 | 7,966 | 14,732 | 18,152 | 29,661 | 28,823 | 23,468 | 24,439 | 20,035 |
Retained Earnings | -4.1% | -98,294 | -94,451 | -92,729 | -88,282 | -85,902 | -82,550 | -79,712 | -74,675 | -69,572 | -66,492 | -49,676 | -45,090 | - | -39,844 | -32,374 |
Additional Paid-In Capital | 0.4% | 90,699 | 90,369 | 88,366 | 82,588 | 83,437 | 83,158 | 83,029 | 83,868 | 84,233 | 85,243 | 78,948 | 67,933 | - | 62,482 | 50,623 |
Shares Outstanding | 16.5% | 343 | 294 | 209 | 25.00 | - | 567.80* | 328.35* | 6.00 | 296.01* | 289.14* | 276.89* | 179.19* | 161.91* | 151.86* | - |
Float | - | - | - | - | 3,324 | - | - | - | 10,593 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | 11.1% | -1,487 | -1,672 | -5,376 | -2,496 | -3,201 | -2,446 | -4,408 | -4,208 | -5,755 | -4,319 | -3,734 | -4,266 | -2,567 | -2,439 | -905 | - | - |
Share Based Compensation | 52.4% | -121 | -254 | 124 | 180 | -121 | 340 | 406 | -59.00 | 1,065 | 5,163 | 577 | 433 | 195 | -12.00 | 236 | - | - |
Cashflow From Investing | - | - | - | - | - | - | -18.00 | - | - | 809 | 5.00 | - | - | - | - | - | - | - |
Cashflow From Financing | 164.4% | 1,380 | 522 | 6,450 | 2,865 | 1,158 | 1,000 | - | - | - | 18,437 | 2,346 | 10,710 | 2,325 | 2,700 | 1,314 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 2,170 | $ 1,427 |
General and administrative | 2,070 | 2,241 |
Total operating expenses | 4,240 | 3,668 |
Loss from operations | (4,240) | (3,668) |
Other income (expenses) | ||
Interest income | 4 | |
Interest expense | (102) | (92) |
Foreign exchange gains | 76 | 95 |
Change in fair value adjustment of derivative and warrant liabilities | 419 | 309 |
Net other income | 393 | 316 |
Net loss for the period before tax benefit | (3,847) | (3,352) |
Income tax benefit | 4 | |
Net loss | (3,843) | (3,352) |
Deemed dividend of 5% on Series C Convertible Preferred stock | (4) | |
Gain on extinguishment of Series A Convertible Preferred stock | 191 | |
Deemed dividend on Series A Convertible Preferred stock | (228) | |
Net loss attributable to common stockholders | $ (3,880) | $ (3,356) |
Basic net loss per common stock (in Dollars per share) | $ (22.14) | $ (6,356.06) |
Weighted-average number of common stock outstanding, Basic (in Shares) | 175,266 | 528 |
Other comprehensive loss, net of tax: | ||
Net loss | $ (3,843) | $ (3,352) |
Change in cumulative translation adjustment | 25 | 84 |
Total comprehensive loss attributable to common stockholders | $ (3,818) | $ (3,268) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash | $ 312 | $ 166 |
Other current assets | 110 | 209 |
Prepaid expenses | 542 | 781 |
Tax credit receivable | 1,331 | 815 |
Total current assets | 2,295 | 1,971 |
Non-current assets: | ||
Property, plant and equipment, net | 18 | 20 |
Intangible assets | 9,656 | 9,871 |
Total assets | 11,969 | 11,862 |
Current liabilities: | ||
Accounts payable | 11,058 | 8,416 |
Accrued liabilities | 1,553 | 1,309 |
Warrant derivative liability | 2,664 | 3,083 |
Income taxes payable | 43 | 59 |
Convertible promissory notes and accrued interest, net of debt discount | 2,690 | 1,300 |
Total current liabilities | 18,008 | 14,167 |
Non-current liabilities: | ||
Deferred tax | 432 | 446 |
Total liabilities | 18,440 | 14,613 |
Commitments and contingencies (Note 16) | ||
Stockholders’ (deficit) equity | ||
Series A Preferred stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at March 31, 2024 and December 31, 2023 were 1,215 and 1,417, respectively (liquidation preference of $4.36 at March 31, 2024) | 1,510 | 1,742 |
Common stock, $0.0001 par value (750,000,000 shares authorized, at March 31, 2024 and December 31, 2023); shares issued and outstanding at March 31, 2024 and December 31, 2023 were 342,774 and 294,347, respectively | ||
Additional paid-in capital | 90,699 | 90,369 |
Accumulated other comprehensive loss | (386) | (411) |
Accumulated deficit | (98,294) | (94,451) |
Total stockholders’ deficit | (6,471) | (2,751) |
Total liabilities, preferred stock and stockholders’ (deficit) equity | $ 11,969 | $ 11,862 |